InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.050 -0.375 (-88.24%)+
Announcement
Release
29 Jan 2026 11:36AM
Price at Release
$0.425
Full Release
download
Summary
Immutep Limited has entered a strategic collaboration with Dr. Reddy’s Laboratories for the commercialization of eftilagimod alfa (efti) outside North America, Europe, Japan, and Greater China, receiving an upfront payment of A$30 million with potential for further milestone payments. The company reported significant progress in its clinical trials, including TACTI-004 for non-small cell lung cancer, with data showing strong response rates and immune activation. Financially, Immutep maintains a solid cash position, anticipated to support operations into Q2 CY2027. The FDA provided positive feedback on efti's optimal dosing, supporting future development endeavors.
Key Points
  • Immutep Limited entered a strategic collaboration with Dr. Reddy’s Laboratories for the commercialization of eftilagimod alfa (efti) outside North America, Europe, Japan, and Greater China.
  • Immutep received an upfront payment of approximately A$30 million and is eligible for up to A$528 million in potential milestones plus royalties.
  • Significant operational progress in the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first-line non-small cell lung cancer with completion of futility analysis anticipated in Q1 CY2026.
  • Data from INSIGHT-003 and EFTISARC-NEO trials demonstrated strong response rates and immune activation.
  • Immutep has a strong cash position with cash, cash equivalents, and term deposits totaling A$99.1 million as at 31 December 2025, extending cash reach into Q2 CY2027.
  • Positive feedback from the FDA on efti’s optimal biological dose for future developments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.